| Name | Title | Contact Details |
|---|---|---|
Bryan Garabrandt |
Chief Technologist | Profile |
MDSave is an online marketplace for customers to shop and compare medical services the same way they shop for everything else. Patients can select their provider based on quality and clear pricing.
Redwood Green Corp. delivers high-quality, safe, sustainable, innovative and accessible cannabis-derived products that support individual well-being. Safety and high quality is a critical commitment from Redwood Green, both for our own brands as well as the partners with whom we do business. The drive behind what we do is rooted in improving well-being and quality of life for a wide range of audiences, ensuring we grow and improve upon what is currently available for consumers in the cannabinoids market. The company is publicly traded and listed on the OTC as RDGC.
Wound Management Technologies is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
At Hyperice, our mission is to provide everyone with the most innovative technology in accelerating recovery time, preventing injury, and enhancing the body`s ability to move more efficiently. All Hyperice products are developed and tested to meet the standards of the world`s best athletes.